46-7911-82
antibody from Invitrogen Antibodies
Targeting: TNFSF15
MGC129934, MGC129935, TL1, TL1A, VEGI, VEGI192A
Antibody data
- Antibody Data
- Antigen structure
- References [5]
- Comments [0]
- Validations
- Flow cytometry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 46-7911-82 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- TL1A Monoclonal Antibody (Tandys1a), PerCP-eFluor™ 710, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- Description: The Tandys1a monoclonal antibody reacts with human and mouse TL1A (TNFSF15). TL1A is a member of the TNF ligand family and is expressed by endothelial cells, tissue macrophages, monocyte-derived dendritic cells, plasma cells and lamina propria-derived lymphocytes. Among peripheral blood cells, TL1A has been shown to be expressed predominantly by CD4+CCR9+ lymphocytes. Its expression has been shown to be induced by TNF alpha, IL-1 alpha and IFN gamma. TL1A binds DR3, which has been shown to be specifically upregulated in Th17 cells among CD4+ T cells. TL1A-deficient dendritic cells are weak in their ability to support Th17 cells in vitro and show decreased severity of EAE. In vivo, TL1A has been shown to be upregulated in tissue lymphocytes of Crohn's Disease and ulcerative colitis patients.
- Antibody clone number
- Tandys1a
- Concentration
- 0.2 mg/mL
Submitted references TNF-like ligand 1A (TL1A) gene knockout leads to ameliorated collagen-induced arthritis in mice: implication of TL1A in humoral immune responses.
Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation.
TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease.
The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells.
Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes.
Wang X, Hu Y, Charpentier T, Lamarre A, Qi S, Wu J, Luo H
Journal of immunology (Baltimore, Md. : 1950) 2013 Dec 1;191(11):5420-9
Journal of immunology (Baltimore, Md. : 1950) 2013 Dec 1;191(11):5420-9
Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation.
Jones GW, Stumhofer JS, Foster T, Twohig JP, Hertzog P, Topley N, Williams AS, Hunter CA, Jenkins BJ, Wang EC, Jones SA
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2011 Jan;25(1):409-19
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2011 Jan;25(1):409-19
TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease.
Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H, Takayama T, Kitazume MT, Okamoto S, Koganei K, Sugita A, Kanai T, Hibi T
Inflammatory bowel diseases 2010 Apr;16(4):568-75
Inflammatory bowel diseases 2010 Apr;16(4):568-75
The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells.
Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR
Journal of immunology (Baltimore, Md. : 1950) 2007 Apr 1;178(7):4033-8
Journal of immunology (Baltimore, Md. : 1950) 2007 Apr 1;178(7):4033-8
Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes.
Papadakis KA, Zhu D, Prehn JL, Landers C, Avanesyan A, Lafkas G, Targan SR
Journal of immunology (Baltimore, Md. : 1950) 2005 Apr 15;174(8):4985-90
Journal of immunology (Baltimore, Md. : 1950) 2005 Apr 15;174(8):4985-90
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Normal human peripheral blood cells were stained with Fixable Viability Dye (FVD) eFluor® 780 (Product # 65-0865-14), then washed and stained with Anti-Human CD4, Anti-Human CCR9, and 0.25 µg of Mouse IgG1 K Isotype Control PerCP-eFluor® 710 (Product # 46-4714-82) (left) or 0.25 µg of Anti-Human/Mouse TL1A PerCP-eFluor® 710 (right). Viable CD4+ lymphocytes were used for analysis.